论文部分内容阅读
目的比较瑞格列奈和二甲双胍治疗继发性失效糖尿病的临床疗效。方法选取徐州医科大学附属第三医院2014—2015年收治的继发性失效糖尿病患者114例,根据治疗方法的不同分为瑞格列奈组(n=57)和二甲双胍组(n=57)。瑞格列奈组患者给予瑞格列奈片治疗,二甲双胍组患者给予二甲双胍缓释片治疗,两组患者均以3个月为1个疗程。比较两组患者治疗前后空腹血糖、餐后2 h血糖及糖化血红蛋白水平,并统计患者不良反应发生情况。结果治疗前,两组患者空腹血糖、餐后2 h血糖、糖化血红蛋白比较,差异无统计学意义(P>0.05);治疗后,瑞格列奈组患者空腹血糖、餐后2 h血糖及糖化血红蛋白水平低于二甲双胍组(P<0.05)。瑞格列奈组患者不良反应发生率低于二甲双胍组(P<0.05)。结论采用瑞格列奈治疗继发性失效糖尿病的临床疗效优于二甲双胍,其可更有效控制患者血糖,且安全性高。
Objective To compare the clinical efficacy of repaglinide and metformin in the treatment of secondary failure of diabetes. Methods A total of 114 patients with secondary failure of diabetes who were admitted to the Third Affiliated Hospital of Xuzhou Medical University from 2014 to 2015 were divided into repaglinide group (n = 57) and metformin group (n = 57) according to the treatment method. Patients in the repaglinide group were treated with repaglinide, and those in the metformin group were treated with metformin sustained-release tablets. Both groups were given a course of 3 months. The fasting blood glucose, postprandial blood glucose and glycosylated hemoglobin levels were compared between the two groups before and after treatment, and the incidence of adverse reactions in the patients was statistically analyzed. Results Before treatment, there was no significant difference in fasting blood glucose, postprandial blood glucose 2 h and HbA1c in both groups (P> 0.05). After treatment, the fasting blood glucose, postprandial blood glucose and glycation Hemoglobin levels were lower in the metformin group (P <0.05). The incidence of adverse reactions in the repaglinide group was lower than that in the metformin group (P <0.05). Conclusion The clinical efficacy of repaglinide in the treatment of secondary failure diabetes is superior to that of metformin, which can be more effective in controlling blood glucose and safety.